Seminars in Pediatric Neurology
Volume 13, Issue 2 , Pages 104-114 , June 2006

The Childhood Limb-Girdle Muscular Dystrophies

  • Volker Straub, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Volker Straub, MD, Institute of Human Genetics, University of Newcastle upon Tyne, International Centre for Life, Central Parkway, Newcastle upon Tyne, NE1 3BZ, UK.
    • ,
  • Kate Bushby, MD

References 

  1. Bönnemann CG, Finkel RS. Sarcolemmal proteins and the spectrum of limb-girdle muscular dystrophies. Semin Pediatr Neurol. 2002;9:81–99
  2. Nowak K, McCullagh K, Poon E, et al. Muscular dystrophies related to the cytoskeleton/nuclear envelope. Novartis Found Symp. 2005;264:98–111discussion 112-117, 227-230
  3. Baghdiguian S, Richard I, Martin M, et al. Pathophysiology of limb girdle muscular dystrophy type 2A: Hypothesis and new insights into the IkappaBalpha/NF-kappaB survival pathway in skeletal muscle. J Mol Med. 2001;79:254–261
  4. Endo T. Aberrant glycosylation of alpha-dystroglycan and congenital muscular dystrophies. Acta Myol. 2005;24:64–69
  5. Frosk P, Weiler T, Nylen E, et al. Limb-girdle muscular dystrophy type 2H associated with mutation in TRIM32, a putative E3-ubiquitin-ligase gene. Am J Hum Genet. 2002;70:663–672
  6. Moreira ES, Wiltshire TJ, Faulkner G, et al. Limb-girdle muscular dystrophy type 2G is caused by mutations in the gene encoding the sarcomeric protein telethonin. Nat Genet. 2000;24:163–166
  7. Udd B, Vihola A, Sarparanta J, et al. Titinopathies and extension of the M-line mutation phenotype beyond distal myopathy and LGMD2J. Neurology. 2005;64:636–642
  8. Angelini C. Limb-girdle muscular dystrophies: Heterogeneity of clinical phenotypes and pathogenetic mechanisms. Acta Myol. 2004;23:130–136
  9. Starling A, Kok F, Passos-Bueno MR, et al. A new form of autosomal dominant limb-girdle muscular dystrophy (LGMD1G) with progressive fingers and toes flexion limitation maps to chromosome 4p21. Eur J Hum Genet. 2004;12:1033–1040
  10. Nigro V. Molecular bases of autosomal recessive limb-girdle muscular dystrophies. Acta Myol. 2003;22:35–42
  11. Fulizio L, Chiara Nascimbeni A, Fanin M, et al. Molecular and muscle pathology in a series of caveolinopathy patients. Hum Mutat. 2005;25:82–89
  12. Walter MC, Petersen JA, Stucka R, Fischer D, et al. FKRP (826C>A) frequently causes limb-girdle muscular dystrophy in German patients. J Med Genet. 2004;41:e50
  13. Mercuri E, Jungbluth H, Muntoni F. Muscle imaging in clinical practice: diagnostic value of muscle magnetic resonance imaging in inherited neuromuscular disorders. Curr Opin Neurol. 2005;18:526–537
  14. Mercuri E, Bushby K, Ricci E, et al. Muscle MRI findings in patients with limb girdle muscular dystrophy with calpain 3 deficiency (LGMD2A) and early contractures. Neuromuscul Disord. 2005;15:164–171
  15. Fischer D, Walter MC, Kesper K, et al. Diagnostic value of muscle MRI in differentiating LGMD2I from other LGMDs. J Neurol. 2005;252:538–547
  16. Georgieva B, Todorova A, Tournev I, et al. 550delA mutation in the calpain 3 (CAPN3) gene: DMD/BMD, SMA, or LGMD2A—Clinically misdiagnosed cases. Am J Med Genet A. 2005;136:399–400
  17. Starling A, de Paula F, Silva H, et al. Calpainopathy: How broad is the spectrum of clinical variability?. J Mol Neurosci. 2003;21:233–236
  18. Benedetti S, Merlini L. Laminopathies: From the heart of the cell to the clinics. Curr Opin Neurol. 2004;17:553–560
  19. Decostre V, Ben Yaou R, Bonne G. Laminopathies affecting skeletal and cardiac muscles: Clinical and pathophysiological aspects. Acta Myol. 2005;24:104–109
  20. Broers JL, Kuijpers HJ, Ostlund C, et al. Both lamin A and lamin C mutations cause lamina instability as well as loss of internal nuclear lamin organization. Exp Cell Res. 2005;304:582–592
  21. Denecke J, Brune T, Feldhaus T, et al. A homozygous ZMPSTE24 null mutation in combination with a heterozygous mutation in the LMNA gene causes Hutchinson-Gilford progeria syndrome (HGPS): Insights into the pathophysiology of HGPS. Hum Mutat. 2006;27:524–531
  22. Pollex RL, Hegele RA. Hutchinson-Gilford progeria syndrome. Clin Genet. 2004;66:375–381
  23. Hegele R. LMNA mutation position predicts organ system involvement in laminopathies. Clin Genet. 2005;68:31–34
  24. Mercuri E, Brown SC, Nihoyannopoulos P, et al. Extreme variability of skeletal and cardiac muscle involvement in patients with mutations in exon 11 of the lamin A/C gene. Muscle Nerve. 2005;31:602–609
  25. Meune C, Van Berlo JH, Anselme F, et al. Primary prevention of sudden death in patients with lamin A/C gene mutations. N Engl J Med. 2006;354:209–210
  26. Perrot A, Sigusch HH, Nagele H, et al. Genetic and phenotypic analysis of dilated cardiomyopathy with conduction system disease: Demand for strategies in the management of presymptomatic lamin A/C mutant carriers. Eur J Heart Fail. 2006;8:484–493
  27. Sylvius N, Tesson F. Lamin A/C and cardiac diseases. Curr Opin Cardiol. 2006;21:159–165
  28. van der Kooi AJ, van Meegen M, Ledderhof TM, et al. Genetic localization of a newly recognized autosomal dominant limb- girdle muscular dystrophy with cardiac involvement (LGMD1B) to chromosome 1q11-21. Am J Hum Genet. 1997;60:891–895
  29. Raffaele Di Barletta M, Ricci E, et al. Different mutations in the LMNA gene cause autosomal dominant and autosomal recessive Emery-Dreifuss muscular dystrophy. Am J Hum Genet. 2000;66:1407–1412
  30. Galbiati F, Volont D, Minetti C, et al. Phenotypic behavior of caveolin-3 mutations that cause autosomal dominant limb girdle muscular dystrophy (LGMD-1C) (Retention of LGMD-1C caveolin-3 mutants within the golgi complex). J Biol Chem. 1999;274:25632–25641
  31. Woodman SE, Sotgia F, Galbiati F, et al. Caveolinopathies: Mutations in caveolin-3 cause four distinct autosomal dominant muscle diseases. Neurology. 2004;62:538–543
  32. Fee DB, So YT, Barraza C, et al. Phenotypic variability associated with Arg26Gln mutation in caveolin3. Muscle Nerve. 2004;30:375–378
  33. Minetti C, Sotgia F, Bruno C, et al. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat Genet. 1998;18:365–368
  34. Alias L, Gallano P, Moreno D, et al. A novel mutation in the caveolin-3 gene causing familial isolated hyperCKaemia. Neuromuscul Disord. 2004;14:321–324
  35. Merlini L, Carbone I, Capanni C, et al. Familial isolated hyperCKaemia associated with a new mutation in the caveolin-3 (CAV-3) gene. J Neurol Neurosurg Psychiatry. 2002;73:65–67
  36. Hayashi T, Arimura T, Ueda K, et al. Identification and functional analysis of a caveolin-3 mutation associated with familial hypertrophic cardiomyopathy. Biochem Biophys Res Commun. 2004;313:178–184
  37. Kubisch C, Ketelsen UP, Goebel I, et al. Autosomal recessive rippling muscle disease with homozygous CAV3 mutations. Ann Neurol. 2005;57:303–304
  38. Kubisch C, Schoser BG, von During M, et al. Homozygous mutations in caveolin-3 cause a severe form of rippling muscle disease. Ann Neurol. 2003;53:512–520
  39. Torbergsen T. Rippling muscle disease: A review. Muscle Nerve Suppl. 2002;11:S103–S107
  40. Messina DN, Speer MC, Pericak-Vance MA, et al. Linkage of familial dilated cardiomyopathy with conduction defect and muscular dystrophy to chromosome 6q23. Am J Hum Genet. 1997;61:909–917
  41. Palenzuela L, Andreu AL, Gamez J, et al. A novel autosomal dominant limb-girdle muscular dystrophy (LGMD 1F) maps to 7q32.1-32.2. Neurology. 2003;61:404–406
  42. Michele DE, Campbell KP. Dystrophin-glycoprotein complex: Post-translational processing and dystroglycan function. J Biol Chem. 2003;278:15457–15460
  43. Grewal PK, Hewitt JE. Glycosylation defects: A new mechanism for muscular dystrophy?. Hum Mol Genet. 2003;12:R259–R264
  44. Hewitt JE, Grewal PK. Glycosylation defects in inherited muscle disease. Cell Mol Life Sci. 2003;60:251–258
  45. Jones KJ, Morgan G, Johnston H, et al. The expanding phenotype of laminin alpha2 chain (merosin) abnormalities: Case series and review. J Med Genet. 2001;38:649–657
  46. Crosbie RH, Lim LE, Moore SA, et al. Molecular and genetic characterization of sarcospan: Insights into sarcoglycan-sarcospan interactions. Hum Mol Genet. 2000;9:2019–2027
  47. Hack AA, Cordier L, Shoturma DI, et al. Muscle degeneration without mechanical injury in sarcoglycan deficiency. Proc Natl Acad Sci U S A. 1999;96:10723–10728
  48. Durbeej M, Campbell KP. Muscular dystrophies involving the dystrophin-glycoprotein complex: An overview of current mouse models. Curr Opin Genet Dev. 2002;12:349–361
  49. Wheeler MT, McNally EM. Sarcoglycans in vascular smooth and striated muscle. Trends Cardiovasc Med. 2003;13:238–243
  50. Frosk P, Greenberg CR, Tennese AA, et al. The most common mutation in FKRP causing limb girdle muscular dystrophy type 2I (LGMD2I) may have occurred only once and is present in Hutterites and other populations. Hum Mutat. 2005;25:38–44
  51. Poppe M, Bourke J, Eagle M, et al. Cardiac and respiratory failure in limb-girdle muscular dystrophy 2I. Ann Neurol. 2004;56:738–741
  52. Balci B, Uyanik G, Dincer P, et al. An autosomal recessive limb girdle muscular dystrophy (LGMD2) with mild mental retardation is allelic to Walker-Warburg syndrome (WWS) caused by a mutation in the POMT1 gene. Neuromuscul Disord. 2005;15:271–275
  53. Dincer P, Balci B, Yuva Y, et al. A novel form of recessive limb girdle muscular dystrophy with mental retardation and abnormal expression of alpha-dystroglycan. Neuromuscul Disord. 2003;13:771–778
  54. Bushby K, Anderson LV, Pollitt C, et al. Abnormal merosin in adults (A new form of late onset muscular dystrophy not linked to chromosome 6q2). Brain. 1998;121:581–588
  55. Sveen ML, Schwartz M, Vissing J. High prevalence and phenotype-genotype correlations of limb girdle muscular dystrophy type 2I in Denmark. Ann Neurol. 2006;59:808–815
  56. Richard I, Broux O, Allamand V, et al. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell. 1995;81:27–40
  57. Saenz A, Leturcq F, Cobo AM, et al. LGMD2A: Genotype-phenotype correlations based on a large mutational survey on the calpain 3 gene. Brain. 2005;128:732–742
  58. Taveau M, Bourg N, Sillon G, et al. Calpain 3 is activated through autolysis within the active site and lyses sarcomeric and sarcolemmal components. Mol Cell Biol. 2003;23:9127–9135
  59. Sorimachi H, Ono Y, Suzuki K. Skeletal muscle-specific calpain, p94, and connectin/titin: Their physiological functions and relationship to limb-girdle muscular dystrophy type 2A. Adv Exp Med Biol. 2000;481:383–395discussion 395-397
  60. Richard I, Roudaut C, Saenz A, et al. Calpainopathy—A survey of mutations and polymorphisms. Am J Hum Genet. 1999;64:1524–1540
  61. Pollitt C, Anderson LV, Pogue R, et al. The phenotype of calpainopathy: Diagnosis based on a multidisciplinary approach. Neuromuscul Disord. 2001;11:287–296
  62. Bansal D, Miyake K, Vogel SS, et al. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature. 2003;423:168–172
  63. Nguyen K, Bassez G, Bernard R, et al. Dysferlin mutations in LGMD2B, Miyoshi myopathy, and atypical dysferlinopathies. Hum Mutat. 2005;26:165
  64. Walter MC, Braun C, Vorgerd M, et al. Variable reduction of caveolin-3 in patients with LGMD2B/MM. J Neurol. 2003;250:1431–1438
  65. Anderson LV, Harrison RM, Pogue R, et al. Secondary reduction in calpain 3 expression in patients with limb girdle muscular dystrophy type 2B and Miyoshi myopathy (primary dysferlinopathies). Neuromuscul Disord. 2000;10:553–559
  66. Cenacchi G, Fanin M, De Giorgi LB, et al. Ultrastructural changes in dysferlinopathy support defective membrane repair mechanism. J Clin Pathol. 2005;58:190–195
  67. Schoser BG, Frosk P, Engel AG, et al. Commonality of TRIM32 mutation in causing sarcotubular myopathy and LGMD2H. Ann Neurol. 2005;57:591–595
  68. Haravuori H, Vihola A, Straub V, et al. Secondary calpain3 deficiency in 2q-linked muscular dystrophy: Titin is the candidate gene. Neurology. 2001;56:869–877
  69. Bushby K, Straub V. Nonmolecular treatment for muscular dystrophies. Curr Opin Neurol. 2005;18:511–518
  70. Bushby K, Muntoni F, Bourke JP. 107th ENMC international workshop: The management of cardiac involvement in muscular dystrophy and myotonic dystrophy, 7th-9th June 2002, Naarden, the Netherlands. Neuromuscul Disord. 2003;13:166–172
  71. Wallgren-Pettersson C, Bushby K, Mellies U, et al. ENMC workshop: Ventilatory support in congenital neuromuscular disorders—Congenital myopathies, congenital muscular dystrophies, congenital myotonic dystrophy and SMA (II) 4-6 April 2003, Naarden, The Netherlands. Neuromuscul Disord. 2004;14:56–69
  72. Jensen MP, Abresch RT, Carter GT, et al. Chronic pain in persons with neuromuscular disease. Arch Phys Med Rehabil. 2005;86:1155–1163
  73. Eagle M. Report on the muscular dystrophy campaign workshop: Exercise in neuromuscular diseases, Newcastle, January 2002. Neuromuscul Disord. 2002;12:975–983
  74. Klingler W, Lehmann-Horn F, Jurkat-Rott K. Complications of anaesthesia in neuromuscular disorders. Neuromuscul Disord. 2005;15:195–206
  75. von der Hagen M, Schallner J, Kaindl AM, et al. Facing the genetic heterogeneity in neuromuscular disorders: linkage analysis as an economic diagnostic approach towards the molecular diagnosis. Neuromuscul Disord. 2006;16:4–13

PII: S1071-9091(06)00096-9

doi: 10.1016/j.spen.2006.06.006

Seminars in Pediatric Neurology
Volume 13, Issue 2 , Pages 104-114 , June 2006

Article Tools

* Image Usage & Resolution